Abstract 2529
Background
Compared with quantification of messenger RNA, a protein level quantification allows for more relevant clinical outcome predictions and the identification of potential therapeutic targets. The aim of this study was to identify a novel protein level signature that was associated with overall survival in patients with resected pancreatic ductal adenocarcinoma (PDAC).
Methods
Data of 105 patients with resected PDAC were retrieved from TRGAted. Reverse-phase protein array (RPPA) quantification data of 218 proteins were collected. By using the LASSO regression model, a protein-level-based classifier was built. Time-dependent receiver operating characteristic (ROC) analysis was used to assess the prognostic accuracy of the classifier. Survival curves were compared by using the Kaplan-Meier analysis.
Results
Using the LASSO model, we built a classifier based on four proteins: BAK, IGFBP2, PDL1, and BRAF-pS445. Survival analysis revealed IGFBP2 and BRAF-pS445 were two favourable prognostic markers, and BAK and PDL1 were unfavourable prognostic markers. Using the classifier, we were able to classify patients between those at high risk of disease progression (high-risk group) and those at low risk of disease progression (low-risk group). Progression-free survival was significantly different between these two groups (11.7 vs 19.9 months for high-risk and low-risk groups, respectively; P < 0.0001). The median overall survival was 13.1 and 36.7 months for the high-risk and low-risk groups, respectively (hazard ratio [HR]: 4.09; 95% CI: 2.39 - 6.98; P < 0.0001). Five-year survival rate was 0% for the high-risk group, and 46% for the low-risk group. The prognostic accuracy (area under the ROC curve) of the classifier were 0.75, 0.77, and 0.81 at 1, 3, and 5 years, respectively. Multivariate Cox regression analysis showed that the classifier was an independent prognostic factor (P < 0.0001).
Conclusions
This protein-level classifier is a novel prognostic tool in patients with resected PDAC. It may facilitate individualized management of patients with this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jie Hua.
Funding
The National Science Fund for Distinguished Young Scholars of China (grant number 81625016).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1988 - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix
Presenter: Semir Vranic
Session: Poster Display session 2
Resources:
Abstract
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract